Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.

Luis RojasSabrina MuñizLidia MedinaJose PeñaFrancisco AcevedoMauricio P PintoCesar Sanchez

Published in: PloS one (2020)

SC-TZM is a cost-saving therapy for Chilean patients with early-stage HER2+ BC. Given their similar efficacy and safety, we suggest the use of SC formulations rather than IV formulations. The use of SC-TZM instead of IV-TZM may have a significant economic impact on public/private healthcare systems.

Keyphrases

healthcare
early breast cancer
early stage
epidermal growth factor receptor
high dose
mental health
health insurance
emergency department
sentinel lymph node
low dose
squamous cell carcinoma
lymph node
health information
tyrosine kinase
locally advanced